Countervail Corporation


Countervail Corporation Awarded Additional $343,000 SBIR Phase II Grant for Continued Development of Medical Countermeasure to Nerve Agents

SBIR funds from the first year of the Phase II component of the fast track grant that were restricted pending the outcome of preliminary studies was released. Use of the funds will be for continued development of galantamine for the pre-treatment application against lethal nerve agent exposure.